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Tyrosine kinase inhibitors (TKIs) are highly effective for the treat-ment of chronic myeloid leukemia (CML), but very few patientsare cured. The major drawbacks regarding TKIs are their low effi-
cacy in eradicating the leukemic stem cells responsible for disease main-
tenance and relapse upon drug cessation. Herein, we performed ribonu-
cleic acid sequencing of flow-sorted primitive (CD34+CD38low) and pro-
genitor (CD34+CD38+) chronic phase CML cells, and identified transcrip-
tional upregulation of 32 cell surface molecules relative to corresponding
normal bone marrow cells. Focusing on novel markers with increased
expression on primitive CML cells, we confirmed upregulation of the
scavenger receptor CD36 and the leptin receptor by flow cytometry. We
also delineate a subpopulation of primitive CML  cells expressing CD36
that is less sensitive to imatinib treatment. Using CD36 targeting anti-
bodies, we show that the CD36 positive cells can be targeted and killed
by antibody-dependent cellular cytotoxicity. In summary, CD36 defines
a subpopulation of primitive CML cells with decreased imatinib sensitiv-
ity that can be effectively targeted and killed using an anti-CD36 anti-
body.
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ABSTRACT
Introduction
Chronic myeloid leukemia (CML) arises when a reciprocal t(9;22) translocation,
generating the BCR/ABL1 fusion gene, occurs in a hematopoietic stem cell (HSC).1,2
Currently, the disease is often controlled by daily administered tyrosine kinase
inhibitors (TKIs) and patients rarely progress into an accelerated phase or blast crisis.3
However, BCR/ABL1 transcripts are still detectable during treatment, even in the
majority of patients with complete clinical and cytogenetic responses.4 Among TKI-
treated patients with undetectable minimal residual disease (MRD), 40-60% lose
their molecular remission after TKI cessation.5 This is generally believed to be caused
by CML stem cells, which are partially resistant to TKI treatment.6-8 Even patients
with undetectable residual disease have been shown to harbor primitive CML cells.9
These primitive CML cells reside within the CD34+CD38low population, and have
been shown by us and others to express both IL1RAP and CD26.10-14 However, the
exact immunophenotype of these primitive CML cells is not clearly defined, and the
identification of additional cell surface molecules on primitive CML cells may trans-
late into new therapeutic opportunities.
Herein, we performed ribonucleic acid (RNA) sequencing of CML CD34+CD38low
cells, and identified CD36 and the leptin receptor (LEPR) as being specifically upreg-
ulated on primitive CML cells compared to corresponding normal bone marrow
(NBM) cells. We further demonstrate that the CD36 expressing subpopulation of
primitive CML cells is less sensitive to imatinib treatment, and that CD36 antibodies
can induce selective killing of CML cells by antibody-dependent cellular cytotoxicity
(ADCC), thus providing a putative new therapeutic oppor-
tunity for targeting imatinib-resistant CML stem cells.
Methods
Patient samples and CD34 enrichment
Bone marrow (BM) and peripheral blood (PB) from TKI-naive
chronic phase CML patients (n=34; Online Supplementary Table S1)
were obtained after written informed consent and in accordance
with the Declaration of Helsinki. Ten of these patients were
included in the NordCML006 study (clinicaltrials.gov identifier:
00852566) and 15 in the ongoing BFORE study (clinicaltrials.gov
identifier: 02130557).15,16 Mononuclear cells were isolated using
lymphoprep (GE Healthcare Bio-Sciences AB, Sweden) and CD34
enrichment was performed using magnetic beads (Miltenyl Biotec,
Germany) according to manufacturer’s instructions. The study was
conducted with the approval of a regional ethics committee in
Lund (Dnr 2011/289). 
Flow cytometric analyses and FACS sorting of primary cells
Analyses of cell surface protein expression and fluorescence-
activated cell sorting (FACS) was performed on a LSR Fortessa or a
FACS Aria II (BD Bioscience, USA). The antibodies and viability
dyes used are listed in Online Supplementary Table S2.  Isotype con-
trols were used at corresponding concentrations. Two or more
CML samples were analyzed for each cell surface marker. Prior to
RNA extraction, carried out according to the manufacturer’s
instructions (Thermo Fisher Inc, USA), viable, single
CD34+CD38low cells (5% lowest CD38 expressing cells of the
CD34+ cells) from CML and NBM were sorted into a PicoPure
RNA Isolation Kit Extraction Buffer (Thermo Fisher Scientific Inc). 
RNA sequencing 
To analyze gene expression, complementary (c)DNA was
amplified using the SMARTer Ultra Low Input RNA Kit for
Sequencing (Takara Bio Europe, France). Sequencing libraries were
prepared from the amplified cDNA using the Nextera Library
DNA Preparation Kit (Illumina, USA). Paired 2x151 base pair (bp)
RNA sequencing was performed on a NextSeq 500 (Illumina). The
reads were aligned to human reference genome hg19 using
TopHat 2.0.7.17 Gene expression values were calculated as frag-
ments per kilobase of transcript per million reads (fpkm) using
Cufflinks 2.2.0.18 A total of ten diagnostic CML samples and four
NBM controls were analyzed. RNA sequencing data have been
deposited at the European Genome-phenome Archive (EGA)
under the accession code EGAS00001002421. Qlucore Omics
Explorer (v 3.1 Qlucore AB, Sweden) was used to identify differ-
entially expressed genes. 
Cell cycle status and cell culture with imatinib 
To distinguish cells in G0/G1 phase from cells in S/G2/M phase
in primary CML patient samples, deep red anthraquinone 5
(DRAQ5; BioStatus, UK) was added after staining for CD34,
CD38, IL1RAP and CD36. Cells were incubated at room tempera-
ture for 20 minutes and subsequently analyzed using a LSR
Fortessa (BD Bioscence). To determine sensitivity to imatinib treat-
ment, 2000 CML cells per well were FACS sorted into 96-well
plates according to CD34+CD38lowIL1RAP+CD36+ and
CD34+CD38lowIL1RAP+CD36- phenotypes (Online Supplementary
Figure S1) and challenged with imatinib at 5μM or dimethyl sulfox-
ide (DMSO) at a corresponding concentration for 72 hours. Viable
cells were evaluated using CountBright Absolute Counting Beads
(Thermo Fisher Inc) and 4',6-diamidino-2-phenylindole (DAPI) on
a LSR Fortessa (BD Bioscience) after three days in culture. 
ADCC assay
For ADCC assays we used polyclonal antibodies targeting
CD36 produced in rabbit (Innovagen, Sweden) and unspecific
polyclonal rabbit immunoglobulin G (IgG) isotypes (Abcam) as
control. Target cells subjected to ADCC were KU812 cells, CD34+-
enriched CML samples and CD34+-enriched NBM samples. Target
cells were labeled with PKH26 (Sigma-Aldrich, USA), plated at
10,000 cells/well and incubated for 30 minutes at room tempera-
ture with antibodies of concentrations between 0.001-10μg/ml.
One hundred thousand natural killer (NK) cells harvested from
healthy donors and isolated using magnetic beads (Milteny Biotec)
were added to each well, and the ADCC effect was analyzed the
following morning using DAPI as a viability marker. Specific
ADCC-induced cell death was calculated according to the follow-
ing formula: 
(Percentage DAPI+ cellsantibody – Percentage DAPI+ cellsno antibody)
/ (0.01 x Percentage DAPI– cellsno antibody). 
Statistical Analyses
Prism 6 (GraphPad Software, USA) was used for statistical
analyses. When possible, the Mann-Whitney U-test was used to
determine statistically significant differences between groups, in
other settings the Student’s t-test was used. The Spearman’s rank
test was used to determine correlations. 
Results
RNA sequencing of CD34+CD38low CML cells 
identifies a distinct gene expression profile 
In order to identify cell surface markers that are upregu-
lated on primitive CML cells, we performed RNA sequenc-
ing of sorted CD34+CD38+ progenitor cells and more prim-
itive CD34+CD38low CML cells from ten newly diagnosed
patients in chronic phase (Figure 1A). Corresponding
healthy BM cells, sorted using the same strategy, were used
as controls (n=4). The CML CD34+CD38low population had
a distinct gene expression profile when compared to normal
CD34+CD38low and CML CD34+CD38+ cells, visualized
using unsupervised principal component analysis with a
variance threshold of 0.27 retaining 1005 genes (Figure 1B).
Using a previously curated list of 1418 genes encoding cell
surface proteins, a two-group comparison revealed a statis-
tically significant leukemia-specific upregulation of 32
genes (fold change >3, Q-value < 0.05) in the primitive
CML cell compartment (Figure 1C,D). Correspondingly, 24
cell surface-associated genes were found to be significantly
downregulated in the same cells (fold change <0.33, Q-
value < 0.05, Online Supplementary Figure S2). 
Validation of cell surface protein expression of 
upregulated genes
To assess if the upregulated genes identified by RNA
sequencing corresponded to an increased protein expres-
sion at the cell surface, we performed flow cytometric
analyses of 16 putative targets using commercially available
antibodies (Table 1 and Online Supplementary Table S2). We
confirmed the previously reported leukemia-specific upreg-
ulation of the following four markers: IL1RAP, IL2RA
(CD25), DPP4 (CD26) and NCAM1 (CD56) within the
CD34+CD38low compartment (Table1).11-13,19 Seven additional
proteins, including CD36, LEPR (CD295), TFRC (CD71),
ITGB3 (CD61), CD7, FCGR2A (CD32), and GP6 were
found to be expressed on primary CD34+CD38low CML cells
by flow cytometry (Table 1). Most of these cell surface pro-
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teins were also expressed on the CML cell lines KU812 and
BV173, whereas fewer displayed expression on K562 and
LAMA84 cells. The remaining five candidate markers
(IL12RBI, HMMR, ECE1, TNFRSF18, and TYRO3) could
not be detected on primary CML cells, possibly due to sub-
optimal antibodies or absent or very low cell surface protein
expression (Table 1). Finally, CD93, known to be expressed
on acute myeloid leukemia (AML) cells and recently report-
ed to be upregulated in CML,20,21 was also expressed on
primitive CML cells, but did not show a significant upregu-
lation in our gene expression data relative to corresponding
NBM cells (Table 1).
CD36 and LEPR are selectively expressed on
CD34+CD38low CML cells compared to corresponding 
NBM cells
Of the newly identified cell surface proteins, CD36,
LEPR, ITGB3 and TFRC showed the highest expression on
CD34+CD38low CML cells, and were therefore evaluated for
expression in NBM. Whereas CD36 and LEPR could not be
CD36 defines CML cells less sensitive to imatinib
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Figure 1. RNA sequencing of sorted primary CML cells from bone marrow of ten newly diagnosed chronic phase patients. (A) Schematic illustration of cell popula-
tions analyzed by RNA sequencing. BM aspirates were used to isolate mononuclear cells and then enrich for CD34 expressing cells with subsequent FACS sorting.
The cells displaying the lowest 5% according to CD38 expression were defined as the primitive population and the highest 80% as the more mature progenitor pop-
ulation. (B) Unsupervised principal component analysis of BM from CML patients (n=10) and healthy donors (n=4) sorted into hematopoietic and leukemic progenitor
and primitive cell populations. (C) Heat map showing overexpression of cell surface genes in the primitive CML population (CD34+CD38low) as compared to healthy
HSCs as determined by RNA sequencing. (D) Schematic figure of total number of transcribed genes detected, number of cell surface associated genes used to filter
the results, number of upregulated genes in the primitive CML cell population, and genes available for validation on protein level. HPC: hematopoietic progenitor cells;
HSC: hematopoietic stem cells; CML: chronic myeloid leukemia; RNA-seq: ribonucleic acid sequencing.
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detected or exhibited low expression on the cell surface of
CD34+CD38low NBM cells, ITGB3 and TFRC showed a
clearly detectable expression, albeit lower than in the corre-
sponding CML cells (Figure 2A). Further, LEPR was not
expressed on more mature CD34+CD38+ cells, whereas
CD36 showed some expression in these cells (Online
Supplementary Figure S3A). When examining specific sub-
populations of normal hematopoietic cells, CD36 displayed
a higher expression in more mature subsets (megakary-
ocyte-erythroid progenitors [MEP], granulocyte-
machrophage progenitors [GMP], and common myeloid
progenitors [CMP]) as compared to more primitive subsets
[HSCs, multipotent progenitors [MPP], and lymphoid-
primed multipotent progenitors [LMPP]; Online
Supplementary Figure S3B).
Notably, the expression of CD36 separated the
CD34+CD38low CML cells into distinct CD36 positive and
negative populations. The overexpression of CD36 in
CD34+CD38low cells in relation to corresponding cells from
healthy BM samples was confirmed in an independent
cohort of 16 CML patients (P=0.0089, Figure 2B). Staining
for LEPR resulted in a weak signal, but extended analyses of
ten primary CML samples with a high leukemic burden in
the CD34+CD38low compartment (as defined by 50-100%
IL1RAP expression, mean 86% IL1RAP+ cells), confirmed a
significantly higher LEPR expression compared with corre-
sponding healthy cells (P=0.002), devoid of LEPR (Figure
2C). Moreover, all CML samples displayed higher mean flu-
orescence intensity (MFI) for LEPR compared with paired
isotype control stained samples, whereas the NBM samples
did not (Online Supplementary Figure S4). Given the specific
expression of LEPR in CML cells, we investigated if CML
cells would respond to leptin.22 However, when assessing
cell growth in vitro and colony forming capacity upon stim-
ulation with leptin, no effects were observed (Online
Supplementary Figure S5A-S5D). We conclude that CD36
and LEPR are specifically upregulated on the surface of
primitive CML cells. 
CD36 expression separates CD34+CD38lowIL1RAP+
CML cells into two distinct populations
We previously demonstrated that IL1RAP expression can
be used to identify BCR/ABL1 positive cells within the
CD34+CD38low compartment of BM cells from CML
patients, with all cells in the IL1RAP positive fraction being
BCR/ABL1 positive.11,13 Because CD36 was found to be
expressed on a subpopulation of the CD34+CD38low CML
cells, we investigated the co-expression of CD36 and
IL1RAP. Although a significant correlation between CD36
and IL1RAP expression was observed (r=0.679, P=0.0048,
Figure 3A), CD36 was distinctly expressed on a subset of
the CD34+CD38lowIL1RAP+ cells (Figure 3B; Online
Supplementary Figure S6). To investigate the co-expression of
IL1RAP and CD36 in relation to the BCR/ABL1 status of the
cells, we sorted cells based on IL1RAP and CD36 expression
within the CD34+CD38low cell fraction from three CML
patients. By fluorescence in situ hybridization (FISH) analy-
ses, we found that on average 98% of
CD34+CD38lowIL1RAP+CD36+ cells and 98% of
CD34+CD38lowIL1RAP+CD36– cells were BCR/ABL1 posi-
tive. By contrast, only 3% of the
CD34+CD38lowIL1RAP–CD36– cells were BCR/ABL1 posi-
tive (Figure 3C,D). Hence, CD36 divides the
CD34+CD38lowIL1RAP+ compartment into a CD36 positive
and a CD36 negative population that are both predomi-
nantly BCR/ABL1 positive.
Primitive CML cells expressing CD36 are less sensitive to
imatinib treatment 
To delineate the difference between the CD36 positive
and negative cell populations of primitive CML cells, we
sorted CD34+CD38lowIL1RAP+CD36+ and CD34+ CD38low
N. Landberg et al.
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Table 1. Cell surface expression of 17 candidate markers in CML cells as determined by flow cytometry.
Primary CMLa CML cell lines
Gene Symbol CD CD34+CD38low CD34+CD38+ KU812 K562 BV173 LAMA84
CD36 CD36 ++ ++ ++ - +/- +
LEPR CD295 + + ++ ++ + ++
TFRC CD71 ++ ++ ++ ++ ++ ++
ITGB3 CD61 ++ ++ ++ - - ++
CD7 CD7 + ++ + - - +
FCGR2A CD32 +/- + ++ ++ ++ ++
GP6 nc + + - - - +/-
IL12RB1 CD212 - - - - - -
HMMR CD168 - - - - +/- -
ECE1 nc - - +/- + - +
TNFRSF18 CD357 - - - + - +
TYRO3 nc - - ++ ++ + ++
IL1RAP* nc ++ ++ ++ - ++ ++
IL2RA* CD25 ++ - ++ + - +
DPP4* CD26 ++ - - - - -
NCAM1* CD56 + +/- - - - -
CD93** CD93 ++ +/- ++ + +/- -
aTwo or more chronic myeloid leukemia (CML) patient samples were analyzed for each cell surface marker. ++: strong expression; +: moderate expression; +/−: expression on
some cells or weak expression; −: no expression; CD: cluster of differentiation; nc: not clustered; *: previously described to be upregulated on CD34+CD38low CML cells; **: did
not pass the thresholds used to identify differentially expressed cell surface markers in the RNA sequencing analysis. 
IL1RAP+CD36− CML cells. Both populations are enriched
for BCR/ABL1 positive cells, given that IL1RAP expression
marks these cells.11,13 The two cell populations exhibited
similar growth and survival after three days in cell culture
(n=3, P=0.48, Figure 3E). Interestingly, the CD36 expressing
cell population showed significantly decreased imatinib
sensitivity as compared to cells lacking CD36 (n=3,
P=0.019, Figure 3F). By contrast, the two cell populations
exhibited a similar sensitivity to nilotinib, suggesting that
the decreased in vitro sensitivity of CD36 expressing cells to
imatinib can be overcome by the second generation TKI
nilotinib (Online Supplementary Figure S7). In order to deter-
mine if the difference in response to imatinib was caused by
differences in quiescence, cell cycle status was evaluated in
three CML patient samples. No difference in cell cycle sta-
tus was observed between CD36 positive and negative cells
within the CD34+CD38lowIL1RAP+ population, with the
majority of cells being in G0 or G1 phase (Figure 3G,H). As
anticipated, more mature CD34+CD38+ cells were cycling
to a higher degree (Online Supplementary Figure S8). These
findings suggest that within the CD34+CD38lowIL1RAP+
compartment, CD36 defines cells that are quiescent and
less sensitive to imatinib treatment. Morever, within the
primitive CD34+CD38lowIL1RAP+ fraction, CD36 positive
and CD36 negative cells showed similar expression of other
putative CML stem cell markers, such as CD25 and CD26
(Online Supplementary Figure S9).
CD36 expression declines during TKI treatment
In order to investigate whether TKI treatment affects
CD36 expression, we first cultured primary CML cells in
vitro. However, CD36 expression rapidly decreased during
in vitro culture even without the presence of TKI (Online
Supplementary Figure S10A-S10C). Subsequently, in a more
CD36 defines CML cells less sensitive to imatinib
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Figure 2. Differentially expressed proteins on primitive CML cells. (A) Representative histograms showing the specific expression of CD36 and LEPR but not ITGB3
and TFRC on leukemic CD34+CD38low cells compared to corresponding cells in NBM. (B) Dot plot showing consistent overexpression of CD36 in the CD34+CD38low cell
fraction in CML samples (n=16) compared to NBM samples (n=5). (C) Overexpression of LEPR in the CD34+CD38low cell fraction in a cohort of ten CML patients with
high IL1RAP expression as compared to NBM samples (n=4). **P<0.01. CML: chronic myeloid leukemia; NBM: normal bone marrow; MFI: mean fluorescence inten-
sity; LEPR: leptin receptor.
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direct assay, we measured CD36 expression in BM cells
from three CML patients treated for three months with
imatinib, bosutinib or dasatinib, respectively. All three sam-
ples showed a substantial reduction of CD36 expression in
the CD34+CD38low compartment as compared to matched
diagnostic samples (Figure 4A). To assess the BCR/ABL1 sta-
tus of the cells during treatment, only patient #11 treated
with imatinib had a sufficient number of cells to allow for
FACS sorting and subsequent FISH analyses. The
CD34+CD38lowCD36+ cells contained 44% BCR/ABL1 posi-
tive cells, whereas CD34+CD38lowCD36- cells only con-
tained 6% BCR/ABL1 positive cells (Figure 4B,C). This
N. Landberg et al.
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Figure 3. A subgroup of primitive CML cells less sensitive to imatinib express CD36 (A) Linear regression and Spearman’s rank correlation show significant correla-
tion between IL1RAP and CD36 expression in primitive CML cells, Y=0.76X + 2.4; r=0.68, P=0.0048. (B) Contour plot of co-expression of IL1RAP and CD36 in a rep-
resentative CML sample (CML #5). (C) FISH on sorted cells from three CML patients showed a mean of 98% BCR/ABL1 positive cells within
CD34+CD38lowIL1RAP+CD36+ cells and 98% BCR/ABL1 positive cells within CD34+CD38lowIL1RAP+CD36– cells. In the CD34+CD38lowIL1RAP–CD36– cell fraction a mean
of 3% were BCR/ABL1 positive; mean based on cells from two CML patients, the third patient had no cells with a CD34+CD38lowIL1RAP–CD36– phenotype. (D) FISH
showing a BCR/ABL1 positive (upper panel) and negative (lower panel) cell. (E) CD34+CD38lowIL1RAP+ CML cells FACS sorted according to CD36 expression does not
appear to differ in cell growth and survival in vitro. The mean of three CML samples is shown; error bars depict standard deviation. (F) CD34+CD38lowIL1RAP+ CML
cells FACS sorted according to CD36 expression and treated with imatinib at a concentration of 5μM show that CD36 expressing cells are more resistant to imatinib
treatment in vitro. The mean of three CML samples is shown; error bars depict standard deviation. (G) Representative histograms from cell cycle analysis using DRAQ5
to determine DNA content show a majority of both CD36+ and CD36– cells in G0/G1 phase within the CD34+CD38lowIL1RAP+ population. (H) Data on cell cycle status
from three CML patient samples are summarized showing mean and standard deviation. *P<0.05. ns; not significant.
patient, with the highest CD36 expression after three
months of TKI treatment, was subsequently the only one of
the three patients that failed to achieve major molecular
response (MMR) after 12 months of treatment, a definition
of optimal response, according to the 2013 European
LeukemiaNet Guidelines (Online Supplementary Table S1).3
CD36 targeting antibodies induce specific killing 
of CML cells
Having found that CD36 marks cells that are less sensi-
tive to imatinib treatment, we next explored CD36 as a
potential target for an antibody-based therapy. To this end,
we generated a polyclonal antibody targeting CD36. In
CD36 defines CML cells less sensitive to imatinib
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Figure 4. CD36 expression is reduced after TKI treatment. (A) BM aspirates
from three CML patients treated with imatinib, bosutinib or dasatinib for three
months showed a substantial reduction of CD36 expression in the
CD34+CD38low compartment as compared to diagnosis. (B) FISH for BCR/ABL1
content on sorted CD34+CD38lowCD36+ and CD34+CD38lowCD36– cells from
patient #11 after 3 months imatinib treatment show a higher BCR/ABL1 con-
tent in CD36 expressing cells. (C) FISH showing a BCR/ABL1 positive (upper
panel) and negative (lower panel) cell. CML: chronic myeloid leukemia. 
Figure 5, Polyclonal antibodies targeting CD36 induce specific killing of CML
cells. (A) The CML cell line KU812 with high CD36 expression can be specifically
killed by a polyclonal rabbit anti-CD36 antibody in a dose-dependent manner by
ADCC when incubated with human NK cells. (B) Primary CD34+ CML cells can
be specifically killed by a polyclonal rabbit anti-CD36 antibody in a dose-depen-
dent manner by ADCC. The mean of three CML samples is shown; error bars
depict standard deviation. (C) NBM samples from healthy donors show a minute
ADCC-induced cell death only at the highest tested concentration of antibody.
The mean of two NBM samples is shown; error bars depict standard deviation.
CML: chronic myeloid leukemia. ADCC: antibody-dependent cellular cytotoxicity;
NBM: normal bone marrow. 
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ADCC assays, we found specific and dose-dependent cell
killing of CD36 expressing KU812 cells (Figure 5A). By con-
trast, the polyclonal CD36 antibody was not associated
with direct toxic effects in the absence of human NK effec-
tor cells (Online Supplementary Figure S11). Notably, we also
found that CD36 can be used as a target for ADCC-medi-
ated cell killing of primary CD34+ CML cells (n=3, Figure
5B), whereas minimal cell death was observed in corre-
sponding NBM cells (n=2, Figure 5C). We conclude that
CD36 targeting antibodies can direct human NK cells to
specifically eliminate CML cells by ADCC.
Discussion
CML is propagated by leukemic stem cells which are par-
tially insensitive to TKI-based therapies, and therefore
believed to be responsible for disease relapse upon with-
drawal of treatment.6-9,23 The identification of cell surface
markers upregulated on primitive CML cells may provide
important biological insights, allow for their prospective
isolation and characterization, and provide novel means for
therapeutic targeting of the treatment resistant cells. 
Herein, we used RNA sequencing of CD34+CD38low
CML cells to identify genes encoding cell surface proteins
upregulated on primitive CML cells and with low or
absent expression on corresponding normal cells. In total,
we identified upregulation of 32 candidate cell surface
markers, of which 16 were further evaluated for protein
expression by flow cytometry. Previous studies aimed at
identifying differentially expressed genes encoding cell
surface markers on candidate CML stem cells mainly
used microarray-based approaches.11,12,24,25 Of the identi-
fied markers, some have previously been described as
being upregulated at the transcriptional level, but apart
from IL2RA (CD25), DPP4 (CD26) and IL1RAP, their bio-
logical roles have not been functionally studied in the
context of chronic phase CML. 
We focused in particular on novel cell surface molecules
present on primitive CML cells and with low to absent
expression on corresponding normal cells, since this may
reveal new therapeutic markers on primitive CML cells that
can be selectively targeted.26 A similar approach recently
allowed us to identify IL1RAP as a therapeutic target on
CML stem cells.11,27 Of the 32 upregulated transcripts, we
validated the cell surface protein expression of four previ-
ously well-studied molecules: IL1RAP, IL2RA, DPP4, and
NCAM1.11-13,19,28 In addition, we identified seven novel cell
surface markers expressed on primitive CML cells: CD36,
LEPR (CD295), TFRC (CD71), ITGB3 (CD61), CD7,
FCGR2A (CD32), and GP6. Of these markers, ITGB3 has
been shown to be upregulated and functionally important
for the growth and homing of AML cells,29 and TFRC has
been described to be expressed at various levels in AML.30
However, we found that only CD36 and LEPR were specif-
ically upregulated on primitive CML cells when compared
to corresponding cells from healthy BM. 
The CD36 molecule is a heavily glycosylated transmem-
brane protein and scavenger receptor expressed in adipose
tissue as well as on thrombocytes, monocytes and
macrophages with a role in phagocytosis.31 It has been sug-
gested to have a role in the formation of atherosclerotic
plaques and the associated inflammation.32 Interestingly, the
expression of CD36 was recently shown to demark a meta-
bolically distinct and treatment refractory subgroup of
leukemic stem cells in AML and blast crisis CML.33
Moreover, CD36 has been shown to be essential in the
metastatic spread of several forms of cancer.34 CD36 anti-
bodies were found to block metastasis in xenograft models
of oral carcinoma, malignant melanoma and breast cancer,
possibly by interfering with the metabolic use of fatty
acids.34 However, the expression of CD36 and its putative
therapeutic importance in chronic phase CML has not been
addressed thus far. We found that CD36 is upregulated on
CD34+CD38low CML cells. Interestingly, we also discovered
that the CD36 expressing subpopulation within the
CD34+CD38lowIL1RAP+ CML fraction was less sensitive to
imatinib treatment, and that these cells could be specifically
killed by ADCC using CD36 antibodies. IL1RAP targeting
has been shown to induce killing of CML cells in a similar
fashion,11,27 but herein we describe that CD36 antibodies
specifically target a cell population within the IL1RAP
expressing population that is less sensitive to imatinib. This
could provide new means with which to target the cells
responsible for relapse after imatinib cessation. However,
whether targeting IL1RAP or CD36 would be the best
approach remains unclear; it is possible that it could  be
beneficial to target both markers for a potentially additive
effect.
Many CML patients are treated with imatinib, and we
therefore sought to determine the effect of imatinib on
CD36 expression. However, CD36 expression is distinctly
reduced during in vitro culture even in the absence of ima-
tinib. Instead, a more direct approach was used, and we
show that CD36 expression within the primitive
CD34+CD38low population is drastically decreased during
the first three months of therapy. It remains of interest, but
is unclear whether the repeated measure of CD36 expres-
sion could act as a surrogate for response during imatinib
treatment. 
In addition to CD36, we also found LEPR to be upregu-
lated on primitive CML cells. LEPR is the receptor for the
well-studied peptide hormone leptin, which is mainly pro-
duced by adipocytes and is known to be involved in the
regulation of bodyweight, BM microenvironment, normal
hematopoiesis, and proliferation of AML cells.35-41 We
observed no growth promoting effects in vitro on primitive
CML cells following stimulation by the ligand leptin, but
the mechanism of action in CML could be different. Indeed,
we note with interest that both CD36 and LEPR are
involved in adipose tissue homeostasis, and a potential
interplay between the adipocyte containing BM microenvi-
ronment and CML stem cells could provide important
growth or survival signals for the neoplastic stem cells. 
In conclusion, we herein identify upregulation of several
novel cell surface markers, including CD36 and LEPR, on
primitive CML cells that may provide novel ways to study
and target CML stem cells. In addition, we define CD36 as
a marker of cells within the primitive CML cell population
in chronic phase CML with decreased sensitivity to ima-
tinib that are vulnerable to antibody-based therapeutic tar-
geting.
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